RecruitingPhase 1Phase 2NCT07246278

Celecoxib in Parkinson Disease as Adjuvant Therapy

Evaluating Safety and Efficacy of Celecoxib in Patients With PD.

Sponsor

Tanta University

Enrollment

80 participants

Start Date

Nov 20, 2025

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease

Summary

Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum. Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD

Eligibility

Min Age: 50 YearsMax Age: 80 Years

Inclusion Criteria3

Age ≥ 18 years.
Both male and female will be included.
Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.

Exclusion Criteria7

Breast feeding
Patients with significant liver and kidney function abnormalities.
Alcohol and / or drug abusers.
Patients with known allergy to the study medications
Patients with known allergy to sulfonamides (cross hypersensitivity with celecoxib).
Pregnant women and women with planned pregnancy.
Patients who are currently using other anti-inflammatory drugs.

Interventions

DRUGLevodopa Carbidopa

Carbidopa/levodopa is the combination of the two medications carbidopa and levodopa. It is primarily used to manage the symptoms of Parkinson's disease

DRUGCelecoxib 200mg

Celecoxib, is a selective cyclooxygenase-2 inhibitor. Prostaglandins (PG) are produced from arachidonic acid by the constitutively expressed cyclooxygenase-1(COX-1)